<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457170</url>
  </required_header>
  <id_info>
    <org_study_id>11/CARD/04</org_study_id>
    <nct_id>NCT01457170</nct_id>
  </id_info>
  <brief_title>Effects of Apelin on the Lung Circulation in Pulmonary Hypertension</brief_title>
  <official_title>Investigating the Acute Pulmonary Vascular Haemodynamic Effects of Apelin in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Golden Jubilee National Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Apelin on the lung circulation. The
      investigators hypothesise that Apelin will relax the lung blood vessels and improve the
      pumping ability of the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apelin is an endogenous peptide with physiological actions in the cardiovascular system and
      is abundantly expressed in the pulmonary vasculature. Pre-clinical models and preliminary
      clinical data indicate that Apelin deficiency may mediate or contribute to the pathogenesis
      of pulmonary hypertension and heart failure. Apelin causes peripheral vasodilatation and
      increased cardiac contractility. The investigators will determine the effects of Apelin on
      the pulmonary circulation in 3 groups; healthy control, people with pulmonary arterial
      hypertension and people with pulmonary hypertension due to heart failure. Each subject will
      receive both Apelin infusion and saline placebo infusion in a crossover design. The infusions
      will be given in a random order which the subject and the investigator will be blinded to.
      The investigators hypothesise that Apelin will have more marked pulmonary haemodynamic
      effects than that observed in the systemic circulation. Moreover, the investigators propose
      that Apelin will have a marked vasodilatory effect on the human pulmonary vasculature and
      reduce pulmonary vascular resistance in patients with pulmonary arterial hypertension or
      pulmonary hypertension due to left heart disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pulmonary vascular resistance</measure>
    <time_frame>5,10,15 and 30 minutes after start of infusion</time_frame>
    <description>We will measure the change in pulmonary vascular resistance after infusion of Apelin during right heart catheterisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systemic vascular resistance</measure>
    <time_frame>5,10,15 and 30 minutes after start of infusion</time_frame>
    <description>We will measure the change in systemic vascular resistance during infusion of Apelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Output</measure>
    <time_frame>5,10,15 and 30 minutes after start of infusion</time_frame>
    <description>We will measure the change in cardiac output after infusion of Apelin during right heart catheterisation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Apelin/Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apelin infusion then crossover to Saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline/Apelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline infusion then crossover to Apelin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apelin</intervention_name>
    <description>During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.</description>
    <arm_group_label>Apelin/Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline (Placebo)</intervention_name>
    <description>During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.</description>
    <arm_group_label>Apelin/Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline (Placebo)</intervention_name>
    <description>During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.</description>
    <arm_group_label>Saline/Apelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apelin</intervention_name>
    <description>During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.</description>
    <arm_group_label>Saline/Apelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PULMONARY ARTERIAL HYPERTENSION

        Inclusion Criteria:

          -  Pulmonary Arterial Hypertension which is Idiopathic, Heritable, associated with
             connective tissue disease or associated with drugs/toxins

          -  mean pulmonary artery pressure &gt;/= 25mmHg

          -  pulmonary capillary wedge pressure &lt; 15 mmHg

          -  normal/reduced cardiac output

          -  stable

          -  WHO functional class II - IV

        Exclusion Criteria:

          -  significant left ventricular dysfunction

          -  chronic lung disease (FEV1 &lt; 60% or abnormal CT)

          -  chronic thromboembolic pulmonary hypertension

        HEART FAILURE

        Inclusion Criteria:

          -  stable on treatment for 3 months prior to study

          -  NYHA grade II - IV

          -  ejection fraction &lt;35%, left ventricular end-diastolic diameter &gt; 5.5 cm and/or
             shortening fraction &lt; 20%

          -  Tricuspid regurgitant velocity &gt;/= 3.0 m/s

        HEALTHY VOLUNTEERS

        Inclusion Criteria:

          -  mean pulmonary artery pressure &lt; 25 mmHg

          -  tricuspid regurgitant velocity &lt; 2.5 m/s

        Exclusion Criteria:

          -  obstructive coronary artery disease

        ALL SUBJECTS

        Exclusion Criteria:

          -  bleeding diathesis

          -  women of childbearing potential without pregnancy test

          -  systolic blood pressure &gt; 190 mmHg or &lt; 100 mmHg

          -  malignant arrhythmias

          -  renal or hepatic failure

          -  haemodynamically significant valvular heart disease

          -  severe or significant co-morbidity

          -  pacemaker

          -  already taking part in another trial

          -  lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Peacock, BSc MPhil MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Service: Golden Jubilee National Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Peacock, BSc MPhil MD</last_name>
    <phone>+44 (0)141 951 5497</phone>
    <email>apeacock@udcf.gla.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Brash, MBChB</last_name>
    <phone>+44 (0)7738569980</phone>
    <email>laurenbrash@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Infirmary Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David E Newby, BM, PhD, DM</last_name>
      <phone>+44 (0)131 242 6515</phone>
      <email>d.e.newby@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>David E Newby, BM, Phd, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin Stirrat, MB ChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew J Peacock, BSc MPhil MD</last_name>
      <phone>+44 (0)141 951 5497</phone>
      <email>apeacock@udcf.gla.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Brash, MB ChB</last_name>
      <phone>+44 (0)7738 569980</phone>
      <email>laurenbrash@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Lauren Brash, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin K Johnson, MBChB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David J Welsh, BSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke SG Howard, MA, MB BChir</last_name>
      <phone>+44 (0)20 83831317</phone>
      <email>l.howard@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Gareth Barnes, MB ChB</last_name>
      <phone>+44 (0)20 83831317</phone>
      <email>g.barnes@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Luke SG Howard, MA, MB BChir</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gareth Barnes, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin R Wilkins, MD, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon J Gibbs, MD, MB Bhir</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2011</study_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Apelin</keyword>
  <keyword>Haemodynamics</keyword>
  <keyword>pulmonary vascular resistance</keyword>
  <keyword>cardiac output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

